Skip to main content

TScan Therapeutics, Inc. (TCRX) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $1.24 (+6.90%)

Consensus Target
$7.50
Upside
+504.8%
Analysts
4
Rating
Buy(2.25)

Price Target Range

Low $3.00Consensus $7.50High $12.00
▲ Current $1.24

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
May 16, 2024Justin ZelinBTIG$12.00+867.7%

TCRX vs Sector & Market

MetricTCRXHealthcare AvgLarge Cap Avg
Analyst Rating2.252.242.41
Analyst Count4818
Target Upside+504.8%+1149.6%+14.9%
P/E Ratio-1.266.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$3M$8M$12M4
2027-12-31$8M$8M$9M4
2028-12-31$15M$27M$32M4
2029-12-31$28M$49M$60M3
2030-12-31$48M$86M$105M3

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-1.60$-0.93$-0.624
2027-12-31$-1.14$-0.87$-0.664
2028-12-31$-1.04$-0.81$-0.643
2029-12-31$-0.78$-0.60$-0.261
2030-12-31$-0.46$-0.36$-0.161

Frequently Asked Questions

What is the analyst consensus for TCRX?

The consensus among 4 analysts covering TScan Therapeutics, Inc. (TCRX) is Buy with an average price target of $7.50.

What is the highest price target for TCRX?

The highest price target for TCRX is $12.00, set by Justin Zelin at BTIG on 2024-05-16.

What is the lowest price target for TCRX?

The lowest price target for TCRX is $12.00, set by Justin Zelin at BTIG on 2024-05-16.

How many analysts cover TCRX?

4 analysts have issued ratings for TScan Therapeutics, Inc. in the past 12 months.

Is TCRX a buy or sell right now?

Based on 4 analyst ratings, TCRX has a consensus rating of Buy (2.25/5) with a +504.8% upside to the consensus target of $7.50.

What are the earnings estimates for TCRX?

Analysts estimate TCRX will report EPS of $-0.93 for the period ending 2026-12-31, with revenue estimated at $8M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.